TRINITY BIOTECH KEVIN LAWSON REGULATORY OFFICER 60 PINEVIEW DR. BUFFALO NY 14031

Re: K172254 Trade/Device Name: Lyme B. Burgdorferi (igm) Marstripe Test Regulation Number: 21 CFR 866.3830 Regulation Name: Treponema pallidum treponemal test reagents Regulatory Class: II Product Code: LSR Dated: July 11, 2017 Received: July 26, 2017

Dear Mr. Lawson:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Kristian M. Roth -S

For:

Uwe Scherf, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

Device Name Lyme B. burgdorferi (IgM) MarStripe Test

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

Theburen tmorhcolletionoationtate veragehour onse,ncd time to review instructions, search existing data sources, gather andmaintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) Summary of Safety and Effectiveness

and 21 CFR 807.92.

1. Submitter Name: Address: Phone Number: Contact Person: Summary Prepared:

Immco Diagnostics, Inc. a Trinity Biotech Company   
60 Pineview Dr., Buffalo, NY 14228   
716-691-0091 ext. 110   
Kevin Lawson   
7-24-2017

2. Device Name: Common Name: Product Code:

Lyme B. burgdorferi (IgM) MarStripe Test Lyme B. burgdorferi (IgM) Immunoblot LSR

Substantially equivalent to: MarDx B. burgdorferi IgM MarBlot Strip Test System (K951709)

contains:

Sample Diluent. Provided for specimen dilutions. Contains BSA and PBS   
Positive Control derived from human serum positive for Lyme disease. Contains ${ < } 0 . 1 \%$ sodium azide   
Negative Control derived from human serum negative for Lyme disease. Contains ${ < } 0 . 1 \%$ sodium azide   
Conjugate. Antihuman IgM-HRP Conjugate binds reactive antibodies to the Substrate   
TMB Substrate. Provides colorimetric reaction for visual read of bound antibodies   
1L with distilled or deionized water.

minute $( \pm 4 \mathrm { \ m i n } )$ u/ur AC, . burgdorferi.

IgM antibody to individual proteins of Borrelia burgdorferi in human serum or plasma $\mathtt { K } _ { 2 ^ { - } }$ EDTA) in samples which have been

6. rall same methodology except that the MarStripe Test has been validated in plasma ( $\mathsf { K } _ { 2 ^ { - } }$ EDTA) as well as serum. Both immunoblot o incorporated in the strip in comparison to the 41kD band of Weakly Reactive Control.

7. Non-clinical Tests: Precision

A Trinity Biotech Company

was $100 \%$ for the low negative, high negative and moderate positive samples. The low positive specimen produced $9 9 . 0 \%$ positive agreement. The cutoff specimen produced $8 1 . 3 \%$ positive agreement.

<table><tr><td>Sample</td><td>n=96</td><td>p41</td><td>p39</td><td>p23</td><td></td></tr><tr><td>1</td><td>Low Negative Band Type</td><td>Neg.</td><td>Neg.</td><td>Neg.</td><td></td></tr><tr><td></td><td>Positives</td><td>0</td><td>0</td><td>0</td><td></td></tr><tr><td></td><td>Negatives</td><td>96</td><td>96</td><td></td><td></td></tr><tr><td></td><td>% Positive</td><td></td><td></td><td></td><td>96 0.0%</td></tr><tr><td>2</td><td></td><td>0.0%</td><td>0.0%</td><td></td><td></td></tr><tr><td></td><td>Low Negative Band Type</td><td></td><td></td><td>Neg.</td><td></td></tr><tr><td></td><td>Positives</td><td>Neg.</td><td>Neg. 0</td><td></td><td></td></tr><tr><td></td><td></td><td>0</td><td></td><td></td><td>3 93</td></tr><tr><td></td><td>Negatives</td><td>96</td><td>96</td><td></td><td>3.1%</td></tr><tr><td>3</td><td>% Positive</td><td>0.0%</td><td>0.0%</td><td></td><td></td></tr><tr><td></td><td>High Negative</td><td></td><td>Neg.</td><td>Neg.</td><td></td></tr><tr><td></td><td>Band Type</td><td>Neg.</td><td>0</td><td></td><td></td></tr><tr><td></td><td>Positives</td><td>0</td><td></td><td></td><td>0 96</td></tr><tr><td></td><td>Negatives</td><td>96</td><td></td><td></td><td>0.0%</td></tr><tr><td>4</td><td>% Positive</td><td>0.0%</td><td>0.0%</td><td></td><td></td></tr><tr><td></td><td>High Negative Band Type</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Positives</td><td>Neg.</td><td>Neg.</td><td></td><td>Cut. 3</td></tr><tr><td></td><td></td><td>0</td><td>0</td><td></td><td>93</td></tr><tr><td></td><td>Negatives</td><td>96</td><td>96</td><td></td><td>3.1%</td></tr><tr><td>5</td><td>% Positive</td><td>0.0%</td><td>0.0%</td><td></td><td></td></tr><tr><td></td><td>Cutoff</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Band Type Positives</td><td>Cut.</td><td>Neg.</td><td>Wpos.</td><td></td></tr><tr><td></td><td>Negatives</td><td>88</td><td>0</td><td></td><td>79 17</td></tr><tr><td></td><td>% Positive</td><td>8 91.7%</td><td>96 0.0%</td><td></td><td>82.3%</td></tr><tr><td>6</td><td>Low Positive</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Band Type</td><td>Pos.</td><td>Neg.</td><td>POs.</td><td></td></tr><tr><td></td><td>Positives</td><td>96</td><td>0</td><td></td><td></td></tr><tr><td></td><td></td><td>0</td><td>96</td><td></td><td>96 0</td></tr><tr><td></td><td>Negatives % Positive</td><td>100.0%</td><td>0.0%</td><td></td><td>100.0%</td></tr><tr><td>7</td><td>Moderate Positive</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Band Type</td><td>Pos.</td><td></td><td></td><td>Pos.</td></tr><tr><td></td><td>Positives</td><td>96</td><td>Neg.</td><td></td><td>96</td></tr><tr><td></td><td>Negatives</td><td>0</td><td>0 96</td><td></td><td></td></tr><tr><td></td><td>% Positive</td><td></td><td>0.0%</td><td></td><td>0 100.0%</td></tr><tr><td>8</td><td></td><td>100.0%</td><td></td><td></td><td></td></tr><tr><td></td><td>Moderate Positive</td><td>Pos.</td><td>Pos.</td><td></td><td></td></tr><tr><td></td><td>Band Type Positives</td><td></td><td>96</td><td></td><td>POs.</td></tr><tr><td></td><td></td><td>96 0</td><td>0</td><td></td><td>96 0</td></tr><tr><td></td><td>Negatives % Positive</td><td>100.0%</td><td>100.0%</td><td></td><td>100.0%</td></tr></table>

Pos $=$ positive band. Neg $=$ negative band. Wpos $=$ weak positive band. Cut $=$ equivocal band

# Reproducibility

agreement was $100 \%$ for both low negative, one high negative and one moderate positive sample. One high negative sample produced $9 9 . 7 \%$ negative agreement, one low positive and one moderate positive sample produced $9 9 . 3 \%$ positive agreement. The cutoff sample produced $6 8 . 4 \%$ positive agreement.

A Trinity Biotech Company

<table><tr><td colspan="2">Sample</td><td>p41</td><td>p39</td><td>p23</td></tr><tr><td colspan="2">1 Low Negative</td><td></td><td></td><td></td></tr><tr><td rowspan="6"></td><td>Band Type</td><td>Neg.</td><td>Neg.</td><td>Neg.</td></tr><tr><td>Positives</td><td>0</td><td>0</td><td>1</td></tr><tr><td>Negatives</td><td>576</td><td>576</td><td>575</td></tr><tr><td>% Positive</td><td>0.0%</td><td>0.0%</td><td>0.2%</td></tr><tr><td>Low Negative</td><td></td><td></td><td></td></tr><tr><td>Band Type</td><td>Neg.</td><td>Neg.</td><td>Neg.</td></tr><tr><td></td><td>Positives</td><td>0</td><td>0</td><td>26</td></tr><tr><td></td><td>Negatives</td><td>576</td><td>576</td><td>550</td></tr><tr><td>3</td><td>% Positive</td><td>0.0%</td><td>0.0%</td><td>4.5%</td></tr><tr><td></td><td>High Negative</td><td></td><td></td><td></td></tr><tr><td rowspan="5"></td><td>Band Type</td><td>Neg.</td><td>Neg.</td><td>Neg.</td></tr><tr><td>Positives</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Negatives</td><td>576</td><td>576</td><td>576</td></tr><tr><td>% Positive</td><td>0.0%</td><td>0.0%</td><td>0.0%</td></tr><tr><td>High Negative</td><td></td><td></td><td></td></tr><tr><td></td><td>Band Type</td><td>Neg.</td><td>Neg.</td><td>Cut.</td></tr><tr><td rowspan="5">5</td><td>Positives</td><td>1</td><td>2</td><td>58</td></tr><tr><td>Negatives</td><td>575</td><td>574</td><td>518</td></tr><tr><td>% Positive</td><td>0.2%</td><td>0.3%</td><td>10.1%</td></tr><tr><td>Cutoff</td><td></td><td></td><td></td></tr><tr><td>Band Type</td><td>Cut.</td><td></td><td></td></tr><tr><td rowspan="5">6</td><td>Positives</td><td>442</td><td>Neg.</td><td>WPos.</td></tr><tr><td>Negatives</td><td></td><td>0</td><td>504 72</td></tr><tr><td>% Positive</td><td>134</td><td>576 0.0%</td><td>87.5%</td></tr><tr><td>Low Positive</td><td>76.7%</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td rowspan="5"></td><td>Band Type</td><td>Pos.</td><td>Neg.</td><td>Pos.</td></tr><tr><td>Positives</td><td>572</td><td>0</td><td>576</td></tr><tr><td>Negatives</td><td>4</td><td>576</td><td>0</td></tr><tr><td>% Positive</td><td>99.3%</td><td>0.0%</td><td>100.0%</td></tr><tr><td>Moderate Positive</td><td></td><td></td><td></td></tr><tr><td></td><td>Band Type</td><td>Pos.</td><td>Neg.</td><td>Pos.</td></tr><tr><td rowspan="8">8</td><td>Positives</td><td>573</td><td>0</td><td>572</td></tr><tr><td>Negatives</td><td>1</td><td>574</td><td>2</td></tr><tr><td>% Positive</td><td>99.8%</td><td>0.0%</td><td>99.7%</td></tr><tr><td>Moderate Positive</td><td></td><td></td><td></td></tr><tr><td>Band Type</td><td>Pos.</td><td>Pos.</td><td>Pos.</td></tr><tr><td>Positives</td><td>576</td><td>572</td><td>576</td></tr><tr><td>Negatives</td><td>0</td><td>4</td><td>0</td></tr><tr><td>% Positive</td><td>100.0%</td><td>99.3%</td><td>100.0%</td></tr></table>

Pos $=$ positive band. Neg $=$ negative band. Wpos $=$ weak positive band. Cut $=$ equivocal band. Note:two replicates of one run are missing due to lack of sample for sample 7.

be $9 9 . 5 \%$ EPY $( 9 5 \% \mathsf { C l } { : } 9 7 . 1 \% - 1 0 0 \% )$ .

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Normal Individuals</td></tr><tr><td rowspan=3 colspan=1>Lyme IgM MarStripeTest</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>219</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>220</td></tr></table>

aial (IgM) MarStripe Test were confirmed positive when tested by the predicate IgM Western blot device.

A Trinity Biotech Company

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=4>Positive specimens/reactive antibody lines - n(%)</td></tr><tr><td rowspan=1 colspan=1>Population</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>p41</td><td rowspan=1 colspan=1>p39</td><td rowspan=1 colspan=1>p23</td></tr><tr><td rowspan=1 colspan=1>E. chafeensis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>3 (30)</td><td rowspan=1 colspan=1>3 (30)</td><td rowspan=1 colspan=1>5 (50)</td><td rowspan=1 colspan=1>4 (40)</td></tr><tr><td rowspan=1 colspan=1>B. microti</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>2 (20)</td><td rowspan=1 colspan=1>2 (20)</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>1 (10)</td></tr><tr><td rowspan=1 colspan=1>L. interogans</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>1 (10)</td></tr><tr><td rowspan=1 colspan=1>H. pylori</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1 (1)</td><td rowspan=1 colspan=1>1 (1)</td><td rowspan=1 colspan=1>1 (1)</td><td rowspan=1 colspan=1>1 (1)</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Influenza</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>1 (10)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Epstein-Barr Virus</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>1 (4.5)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Rocky Mountain Spotted fever</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Parvovirus B19</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>2 (22.2)</td><td rowspan=1 colspan=1>1 (11.1)</td></tr><tr><td rowspan=1 colspan=1>Systmatic lupus erythematosus</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Celiac</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td><td rowspan=1 colspan=1>0 (0)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>7 (2.8)</td><td rowspan=1 colspan=1>8 (3.2)</td><td rowspan=1 colspan=1>11 (4.4)</td><td rowspan=1 colspan=1>8 (3.2)</td></tr></table>

Interference: Two Lyme IgM negative and three Lyme IgM positive sera were spiked with hemoglobin $( 2 \tt g / L )$ ,unconjugated bilirubin $( 3 4 2 \mu \mathrm { m o l / L } )$ , RF $( 1 0 0 ~ \mathrm { | U / m | } )$ , triglycerides (3.7 mmol/L) and total cholesterol $\{ 1 3 \ \mathrm { m m o l / L } \}$ and tested using this assay. Samples were tested with and without interfering agents. Qualitative agreement was $100 \%$ for all specimens.

atCbliulea o agreement for all pairs was $100 \%$ .

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Type</td><td rowspan=1 colspan=1>p41</td><td rowspan=1 colspan=1>p39</td><td rowspan=1 colspan=1>p23</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Band %Agrmt</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>POS</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>POS</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>E</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>G</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>G</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>H</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>H</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>J</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>POS</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>J</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>POS</td></tr><tr><td rowspan=1 colspan=1>K</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>K</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>L</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>L</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>100</td></tr></table>

A Trinity Biotech Company

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>O</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>P</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>P</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>Q</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Q</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>NEG</td></tr><tr><td rowspan=1 colspan=1>T</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td><td rowspan=2 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>T</td><td rowspan=1 colspan=1>Plasma</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NEG</td></tr></table>

1. $0 =$ negative band result. ${ \boldsymbol { 1 } } =$ positive band result.

# 8Clinical Tests:

y distinct study sites. The specimens testing positive $( n { = } 6 7 6 )$ on a FDA cleared first-step EIA were tested with Lyme B. burgdorferi a Disease 22. The results are summarized below.

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Predicate IgM WB</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Lyme IgMMarStripe Test</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>302</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>325</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>330</td><td rowspan=1 colspan=1>351</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>323</td><td rowspan=1 colspan=1>553</td><td rowspan=1 colspan=1>676</td></tr></table>

Positive $\%$ Agreement: $9 3 . 5 \%$ $9 5 \%$ CI: 90.1% - 95.8%) Negative $\%$ Agreement: $9 3 . 5 \%$ $9 5 \%$ CI: 90.2% - 95.7%)

S compared with that of the predicate device.

<table><tr><td rowspan=2 colspan=1>Interval</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Lyme IgM MarStripe Test</td><td rowspan=1 colspan=2>Predicate IgM WB</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Early Lyme (stage 1)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>42.1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>47.4</td></tr><tr><td rowspan=1 colspan=1>Early disseminated (stage 2)</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>Late Lyme (stage 3)</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>18.4</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>19.5</td></tr></table>

Sensitivity Comparison: Lyme B. burgdorferi (IgM) MarStripe Test: $1 8 . 4 \%$ (16/87) $9 5 \%$ CI: $1 1 . 2 \% - 2 8 . 4 \%$ Predicate device: $1 9 . 5 \%$ (17/87) $9 5 \%$ CI: $1 2 . 1 \% - 2 9 . 7 \% \big )$ Difference in proportion: $1 . 1 \%$

CC anele panel omen issono n ev m issValt $\mathtt { n } = \mathtt { 1 0 }$ ,Lyme Disease Basic Research Panel $\mathtt { n } = 3 2$ ) were tested on the Lyme B. burgdorferi (IgM) MarStripe Test and the predicate device.

A Trinity Biotech Company

<table><tr><td rowspan=2 colspan=1>Interval</td><td rowspan=2 colspan=1>n</td><td rowspan=1 colspan=2>Lyme IgMMarStripe Test</td><td rowspan=1 colspan=2>Predicate IgM WB</td></tr><tr><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Early Lyme (stage 1)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>Early disseminated (stage 2)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Late Lyme (stage 3)</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>23.8</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>31.0</td></tr></table>

characterized serum panel. This does not imply an endorsement of the assay by the CDC.

by Trinity Biotech

![](images/076fab9434b2bcf522f03b0366fd9e2c6f7a9e88cf18121262bc22a4d6fd92c0.jpg)

Kevin J. Lawson VP Regulatory Affairs